🔴 Amylyx Pharmaceuticals is trading 4.46% down today after upsized $575 million public offering

Amylyx Pharmaceuticals is trading 4.46% down at $35.79 after completing an upsized public offering that raised approximately $575.2 million before expenses.

• The offering comprised 16,203,500 shares at $35.50 each and closed August 21, 2026.
• The issuance likely pressured the stock through dilution and offering-price anchoring, despite positive Phase 3 LUCIDITY results and a stronger biotech sector.